Join to View Full Profile
250 25th Ave NSte 100Nashville, TN 37203
Phone+1 615-320-5090
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Johanna Bendell, MD is an oncologist in Nashville, Tennessee. She is currently licensed to practice medicine in Tennessee and North Carolina.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
TN State Medical License 2008 - 2023
NC State Medical License 2020 - 2022
Publications & Presentations
PubMed
- A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.Ben Tran, Mark Voskoboynik, Johanna Bendell, Martin Gutierrez, Charlotte Lemech
Immunotherapy. 2024-01-01 - 32 citationsAnti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.Tae Won Kim, Philippe L Bedard, Patricia LoRusso, Michael S Gordon, Johanna Bendell
JAMA Oncology. 2023-11-01 - 19 citationsTumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.Lucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, Junghyun Lim, Kerrigan Blake
Nature Communications. 2023-09-23
Press Mentions
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast CancerMay 31st, 2025- Pfizer’s BRAFTOVI® Combination Regimen Halves Mortality Risk in BRAF V600E-Mutant Metastatic Colorectal CancerMay 31st, 2025
- Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal CancerMay 30th, 2025
- Join now to see all
